Who are Methotrexate + targeted therapy administration's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/methotrexate-targeted-therapy-administration.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Methotrexate + targeted therapy administration — Competitive Intelligence Brief

Methotrexate + targeted therapy administration (Methotrexate + targeted therapy administration) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy with targeted agent. Area: Oncology.

marketed Combination chemotherapy with targeted agent Dihydrofolate reductase (methotrexate component); targeted agent varies by protocol Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Methotrexate + targeted therapy administration (Methotrexate + targeted therapy administration) — University Hospital, Strasbourg, France. Methotrexate inhibits dihydrofolate reductase to suppress cell proliferation and immune activation, often combined with targeted therapies that inhibit specific oncogenic pathways or immune checkpoints.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Methotrexate + targeted therapy administration TARGET	Methotrexate + targeted therapy administration	University Hospital, Strasbourg, France	marketed	Combination chemotherapy with targeted agent	Dihydrofolate reductase (methotrexate component); targeted agent varies by protocol

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy with targeted agent class)

University Hospital, Strasbourg, France · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Methotrexate + targeted therapy administration — Competitive Intelligence Brief. https://druglandscape.com/ci/methotrexate-targeted-therapy-administration. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab